<DOC>
	<DOCNO>NCT02674568</DOCNO>
	<brief_summary>The purpose study determine efficacy rovalpituzumab tesirine third-line later treatment subject relapse refractory delta-like protein 3 ( DLL3 ) express small cell lung cancer ( SCLC ) .</brief_summary>
	<brief_title>Study Rovalpituzumab Tesirine ( SC16LD6.5 ) Third-line Later Treatment Subjects With Relapsed Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer ( TRINITY )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<criteria>1 . Adult age 18 year old 2 . Histologically confirm smallcell lung cancer ( SCLC ) document disease progression least 2 prior systemic regimen , include least one platinumbased regimen 3 . DLL3expressing SCLC base central immunohistochemistry ( IHC ) assessment bank otherwise representative tumor tissue . Positive define stain ≥ 1 % tumor cell . 4 . Measurable disease define RECIST 1.1 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 6 . Minimum life expectancy least 12 week 7 . Subjects history central nervous system ( CNS ) metastases must documentation stable improve status base brain image least 2 week completion definitive treatment within 2 week prior first dose Study Drug , stable dose corticosteroid . 8 . Recovery Grade 1 clinically significant toxicity ( exclude alopecia ) prior initiation study drug administration 9 . Adequate hematologic organ function confirm laboratory value 10 . Last dose prior therapy administer following time interval first dose study drug : Chemotherapy , small molecule inhibitor , radiation , and/or investigational anticancer agent ( exclude investigational monoclonal antibody ) : 2 week Immunecheckpoint inhibitor ( i.e. , antiPD1 , antiPDL1 , antiCTLA4 ) : 4 week Other monoclonal antibody , antibodydrug conjugate , radioimmunoconjugates , Tcell cellbased therapy : 4 week ( 2 week document disease progression ) 11 . Females childbearing potential must negative beta human chorionic gonadotropin ( βhCG ) pregnancy test result within 7 day prior first dose study drug . Females nonchildbearing potential postmenopausal great 1 year bilateral tubal ligation hysterectomy . 1 . Any significant medical condition , include suggest screen laboratory finding , opinion investigator sponsor , may place subject undue risk study , include necessarily limit uncontrolled hypertension and/or diabetes , clinically significant pulmonary disease ( e.g. , chronic obstructive pulmonary disease require hospitalization within 6 month ) neurological disorder ( e.g. , seizure disorder active within 6 month ) 2 . Documented history cerebral vascular event ( stroke transient ischemic attack ) , unstable angina , myocardial infarction , cardiac symptom consistent New York Heart Association ( NYHA ) Class IIIIV within 6 month prior first dose study drug 3 . Recent ongoing serious infection , include : Any active grade 3 high ( per NCI CTCAE version 4.03 ) viral , bacterial , fungal infection within 2 week first dose study drug . Routine antimicrobial prophylaxis permit . Known seropositivity active infection human immunodeficiency virus ( HIV ) Active Hepatitis B ( surface antigen expression polymerase chain reaction ) C ( polymerase chain reaction ) infection hepatitisrelated antiviral therapy within 6 month first dose study drug . 4 . Women breastfeed 5 . Systemic therapy corticosteroid &gt; 20 mg/day prednisone equivalent within 1 week prior first dose study drug 6 . History another invasive malignancy remission least 3 year . Exceptions 3 year limit include nonmelanoma skin cancer , curatively treat localized prostate cancer , cervical cancer situ biopsy squamous intraepithelial lesion PAP smear 7 . Prior exposure pyrrolobenzodiazepine ( PBD ) base drug , know hypersensitivity rovalpituzumab tesirine excipient contain drug formulation , unless undergoing retreatment rovalpituzumab tesirine context protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>SCLC</keyword>
	<keyword>Small Cell Lung Cancer</keyword>
	<keyword>DLL3</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
</DOC>